EcoDrugPlus

Angiotensin I Converting Enzyme

Ensembl ID : ENSDNOG00000000903
Gene Symbol: ACE
4 Cross references
92 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSDNOG00000018776
Gene Symbol: AGTR1
2 Cross references
214 Possible Orthologues:

Apelin Receptor

Ensembl ID : ENSDNOG00000006063
Gene Symbol: APLNR
4 Cross references
172 Possible Orthologues:

Aph-1 Homolog A, Gamma-Secretase Subunit

Ensembl ID : ENSDNOG00000007194
Gene Symbol: APH1A
2 Cross references
138 Possible Orthologues:

Aph-1 Homolog B, Gamma-Secretase Subunit

Ensembl ID : ENSDNOG00000039993
Gene Symbol: APH1B
4 Cross references
193 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSDNOG00000042234
Gene Symbol: APEX1
2 Cross references
214 Possible Orthologues:

Arachidonate 12-Lipoxygenase, 12s Type

Ensembl ID : ENSDNOG00000015512
Gene Symbol: ALOX12
4 Cross references
200 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSDNOG00000019443
Gene Symbol: ALOX5
4 Cross references
223 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSDNOG00000047673
Gene Symbol: ALOX5AP
2 Cross references
201 Possible Orthologues:

Arginine Vasopressin Receptor 1a

Ensembl ID : ENSDNOG00000041082
Gene Symbol: AVPR1A
4 Cross references
268 Possible Orthologues:

Arginine Vasopressin Receptor 1b

Ensembl ID : ENSDNOG00000009751
Gene Symbol: AVPR1B
4 Cross references
137 Possible Orthologues:

Arginine Vasopressin Receptor 2

Ensembl ID : ENSDNOG00000043252
Gene Symbol: AVPR2
4 Cross references
251 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).